Acute kidney injury among patients with chronic kidney disease
慢性肾脏病患者的急性肾损伤
基本信息
- 批准号:9978765
- 负责人:
- 金额:$ 67.97万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2018
- 资助国家:美国
- 起止时间:2018-07-01 至 2022-06-30
- 项目状态:已结题
- 来源:
- 关键词:AccountingAcute Renal Failure with Renal Papillary NecrosisAddressAdultAffectBiological MarkersCCL2 geneCHI3L1 geneCardiovascular DiseasesCardiovascular systemCharacteristicsChitinaseChronic Kidney FailureChronic Kidney InsufficiencyCodeCohort StudiesConflict (Psychology)CreatinineDataData AnalysesData CollectionDiagnosticDisease ProgressionEventExperimental DesignsFibrosisFutureGlomerular Filtration RateHospital RecordsHospitalizationHumanIncidenceInflammationInjuryInpatientsInterleukin-18InvestigationKidney DiseasesKnowledgeLiteratureLongitudinal StudiesMeasurementMuscular AtrophyNatural HistoryOutcomePatient-Focused OutcomesPatientsPerformancePhasePhenotypePlasmaPlayPopulation HeterogeneityProspective cohortProspective cohort studyProteinsProteinuriaProtocols documentationPublishingRenal functionReportingResearchResidual stateRiskRisk FactorsRoleSerumSeveritiesShapesUrinebasecardiovascular risk factorclinical carecohortcostfollow-uphigh riskimproved outcomeinterestmuscle formpost gamma-globulinsprospectiverat KIM-1 proteinrepairedsecondary analysis
项目摘要
PROJECT SUMMARY
Acute kidney injury (AKI) is one of the major manifestations of kidney disease. AKI's importance is
underscored by recent studies reporting that its incidence is increasing. AKI disproportionately affects those
with chronic kidney disease (CKD), so it is compelling to embed the investigation of AKI in the largest and most
comprehensive prospective cohort study of CKD in the US, the Chronic Renal Insufficiency Cohort (CRIC)
study.
We propose to comprehensively evaluate all inpatient hospital records for all enrollees in CRIC Phases 3 and 4
(from 2013-2021) to identify episodes AKI, define their severity and examine their sequelae. CRIC was
launched over a dozen years ago as a study of the natural history of CKD. It now offers an under-utilized but
potentially unmatched opportunity to advance our understanding of the role AKI plays in shaping the natural
history of CKD. Particularly valuable is the availability of research protocol-driven collection of data and
biospecimens both before and after episodes of hospitalized AKI.
Our Specific Aims are: 1) to evaluate the associations of hospitalized AKI and its severity with subsequent rate
of loss of renal function after taking into account pre-AKI estimated glomerular filtration rate (eGFR) slope and
pre-AKI proteinuria level; 2) to evaluate the associations of hospitalized AKI and its severity with change in
proteinuria and to assess the relation between post-AKI proteinuria level and subsequent CKD progression; 3)
to define the risk of future cardiovascular events associated with hospitalized AKI and its severity; 4) to
determine the association of hospitalized AKI with changes in levels of biomarkers of injury, inflammation and
fibrosis.
Compared with all the other studies based on observational data now published in the literature, ours will have
a much more rigorous experimental design, greatly reducing residual confounding and other biases. Our
findings may challenge the current reigning paradigm that mild to moderate episodes of AKI worsen the
course/outcome of CKD.
项目摘要
急性肾脏损伤(AKI)是肾脏疾病的主要表现之一。 Aki的重要性是
最近的研究强调了其发病率正在增加。 Aki不成比例地影响那些
有慢性肾脏疾病(CKD),因此将AKI的研究嵌入最大,最大,最大的
美国CKD的全面前瞻性队列研究,慢性肾功能不全队列(CRIC)
学习。
我们建议全面评估CRIC阶段所有参与者的所有住院医院记录3和4
(从2013-2021开始)识别情节AKI,定义其严重程度并检查其后遗症。克里克是
作为对CKD的自然历史的研究,启动了十多年。现在它提供了未充分利用的但
潜在的无与伦比的机会,可以促进我们对AKI在塑造自然作用的作用的理解
CKD的历史。特别有价值的是研究协议驱动的数据收集的可用性和
在住院的AKI发作之前和之后,生物测量。
我们的具体目的是:1)评估住院AKI的关联及其与随后的比率
肾功能丧失后,AKI估计的肾小球滤过率(EGFR)斜率和
阿基前蛋白尿水平; 2)评估住院AKI的关联及其与变化的严重性
蛋白尿并评估蛋白尿后蛋白尿水平与随后的CKD进展之间的关系; 3)
定义与住院AKI及其严重性相关的未来心血管事件的风险; 4)到
确定住院的AKI与伤害,炎症和
纤维化。
与现在在文献中发表的观察数据的所有其他研究相比,我们的研究
更严格的实验设计,大大减少了残留混杂和其他偏见。我们的
调查结果可能会挑战当前的统治范式,即Aki的轻度至中度发作使
CKD的课程/结果。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Chi-yuan Hsu其他文献
Chi-yuan Hsu的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Chi-yuan Hsu', 18)}}的其他基金
Living Donor Extended Time Outcomes (LETO) Study
活体捐赠者延长时间结果 (LETO) 研究
- 批准号:
10413009 - 财政年份:2019
- 资助金额:
$ 67.97万 - 项目类别:
Living Donor Extended Time Outcomes (LETO) Study
活体捐赠者延长时间结果 (LETO) 研究
- 批准号:
10164513 - 财政年份:2019
- 资助金额:
$ 67.97万 - 项目类别:
Living Donor Extended Time Outcomes (LETO) Study
活体捐赠者延长时间结果 (LETO) 研究
- 批准号:
9906216 - 财政年份:2019
- 资助金额:
$ 67.97万 - 项目类别:
Living Donor Extended Time Outcomes (LETO) Study
活体捐赠者延长时间结果 (LETO) 研究
- 批准号:
10652284 - 财政年份:2019
- 资助金额:
$ 67.97万 - 项目类别:
CODE-AKI: COnservative Dialysis to Enhance AKI Recovery
CODE-AKI:保守透析促进 AKI 恢复
- 批准号:
10912233 - 财政年份:2019
- 资助金额:
$ 67.97万 - 项目类别:
CODE-AKI: COnservative Dialysis to Enhance AKI Recovery
CODE-AKI:保守透析促进 AKI 恢复
- 批准号:
10203956 - 财政年份:2019
- 资助金额:
$ 67.97万 - 项目类别:
CODE-AKI: COnservative Dialysis to Enhance AKI Recovery
CODE-AKI:保守透析促进 AKI 恢复
- 批准号:
10655505 - 财政年份:2019
- 资助金额:
$ 67.97万 - 项目类别:
CODE-AKI: COnservative Dialysis to Enhance AKI Recovery
CODE-AKI:保守透析促进 AKI 恢复
- 批准号:
10015269 - 财政年份:2019
- 资助金额:
$ 67.97万 - 项目类别:
CODE-AKI: COnservative Dialysis to Enhance AKI Recovery
CODE-AKI:保守透析促进 AKI 恢复
- 批准号:
10424430 - 财政年份:2019
- 资助金额:
$ 67.97万 - 项目类别:
Living Donor Extended Time Outcomes (LETO) Study
活体捐赠者延长时间结果 (LETO) 研究
- 批准号:
10178007 - 财政年份:2019
- 资助金额:
$ 67.97万 - 项目类别:
相似海外基金
A Randomized Clinical Trial of the Safety and FeasibiLity of Metformin as a Treatment for sepsis induced AKI (LiMiT AKI)
二甲双胍治疗脓毒症引起的 AKI (LiMiT AKI) 的安全性和可行性的随机临床试验
- 批准号:
10656829 - 财政年份:2023
- 资助金额:
$ 67.97万 - 项目类别:
Promoting De-Implementation of Inappropriate Antimicrobial Use in Cardiac Device Procedures By Expanding Audit and Feedback
通过扩大审计和反馈,促进消除心脏装置手术中不当使用抗菌药物的情况
- 批准号:
10404914 - 财政年份:2021
- 资助金额:
$ 67.97万 - 项目类别:
(MEnD-AKI) Multicenter Implementation of an Electronic Decision Support System for Drug-associated AKI
(MEnD-AKI) 药物相关 AKI 电子决策支持系统的多中心实施
- 批准号:
10414976 - 财政年份:2021
- 资助金额:
$ 67.97万 - 项目类别:
Promoting De-Implementation of Inappropriate Antimicrobial Use in Cardiac Device Procedures By Expanding Audit and Feedback
通过扩大审计和反馈,促进消除心脏装置手术中不当使用抗菌药物的情况
- 批准号:
10067042 - 财政年份:2021
- 资助金额:
$ 67.97万 - 项目类别: